THE USE OF TOCILIZUMAB IN THE TREATMENT OF A SYSTEMIC VARIANT OF JUVENILE IDIOPATHIC ARTHRITIS
To date, in the arsenal of drugs used in the treatment of juvenile idiopathic arthritis with systemic onset, there is a drug Тocilizumab, which is a recombinant humanized monoclonal antibody to the IL-6 receptor. The article presents a clinical case of the use of Тocilizumab in a child with a systemic variant of juvenile idiopathic arthritis with ineffective treatment with glucocorticosteroids and Мethotrexate.